63.70
-0.42 (-0.66%)
| Previous Close | 64.12 |
| Open | 64.15 |
| Volume | 1,985,612 |
| Avg. Volume (3M) | 2,253,788 |
| Market Cap | 12,268,492,800 |
| Price / Earnings (TTM) | 155.37 |
| Price / Earnings (Forward) | 10.41 |
| Price / Sales | 3.85 |
| Price / Book | 4.26 |
| 52 Weeks Range | |
| Earnings Date | 29 Oct 2024 - 4 Nov 2024 |
| Profit Margin | 2.52% |
| Operating Margin (TTM) | -45.67% |
| Diluted EPS (TTM) | 0.410 |
| Quarterly Revenue Growth (YOY) | 9.30% |
| Total Debt/Equity (MRQ) | 1.25% |
| Current Ratio (MRQ) | 1.92 |
| Operating Cash Flow (TTM) | -61.19 M |
| Levered Free Cash Flow (TTM) | 269.19 M |
| Return on Assets (TTM) | 0.39% |
| Return on Equity (TTM) | 2.52% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Incyte Corporation | Bearish | Bearish |
Stockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.5 |
| Average | -0.38 |
|
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Core |
| % Held by Insiders | 2.05% |
| % Held by Institutions | 105.89% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 92.00 (Guggenheim, 44.43%) | Buy |
| Median | 68.00 (6.75%) | |
| Low | 60.00 (Deutsche Bank, -5.81%) | Hold |
| Average | 72.56 (13.91%) | |
| Total | 3 Buy, 6 Hold | |
| Avg. Price @ Call | 65.87 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 10 Oct 2024 | 62.00 (-2.67%) | Hold | 65.37 |
| Truist Securities | 18 Sep 2024 | 74.00 (16.17%) | Hold | 65.17 |
| B of A Securities | 16 Sep 2024 | 68.00 (6.75%) | Hold | 66.41 |
| 31 Jul 2024 | 66.00 (3.61%) | Hold | 65.07 | |
| Guggenheim | 16 Sep 2024 | 92.00 (44.43%) | Buy | 66.41 |
| RBC Capital | 03 Sep 2024 | 67.00 (5.18%) | Hold | 66.31 |
| 15 Aug 2024 | 67.00 (5.18%) | Hold | 61.68 | |
| Deutsche Bank | 01 Aug 2024 | 60.00 (-5.81%) | Hold | 64.42 |
| Citigroup | 31 Jul 2024 | 88.00 (38.15%) | Buy | 65.07 |
| JP Morgan | 31 Jul 2024 | 61.00 (-4.24%) | Hold | 65.07 |
| Oppenheimer | 26 Jul 2024 | 81.00 (27.16%) | Buy | 68.61 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |